# Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis

> **NCT02770040** · PHASE4 · COMPLETED · sponsor: **Austin Health** · enrollment: 138 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT02770040
- **Lead sponsor:** Austin Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-18
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-09-07
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770040, "Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02770040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*